2025-08-20 - Analysis Report
Okay, here's a report summarizing the analysis of Recursion Pharmaceuticals Inc. (RXRX), along with key figures and insights.

## Recursion Pharmaceuticals Inc. (RXRX) Analysis

**Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover and develop novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

*   **RXRX Cumulative Return:** -45.47%
*   **VOO Cumulative Return:** 39.95%
*   **Absolute Divergence:** -87.0 (RXRX underperforming VOO)
*   **Divergence Range:** Max: 33.2, Min: -90.5
*   **Relative Divergence:** 2.8 (RXRX is near its worst historical underperformance relative to VOO)

**Analysis:** RXRX has significantly underperformed the S&P 500 over the observed period. The relative divergence indicates that this underperformance is near the lower end of its historical range, meaning it is currently underperforming VOO more than it typically has in the past.

### Alpha, Beta Analysis

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
| :---------- | :----- | :----- | :------ | :----- | :------- |
| 2021-2023 | 5.0%   | 73.6% | -1.0%   | -0.1  | 4.0    |
| 2022-2024 | 0.0%   | 73.6% | -25.0% | 0.1  | 2.7    |
| 2023-2025 | 6.0%   | 73.6% | -47.0% | 0.1  | 2.2    |

**Analysis:** RXRX's data reveals some critical insights. First, the MDD (Maximum Drawdown) is consistently high at 73.6% across all periods, which indicates significant risk.
Second, the Alpha is negative, indicating that RXRX has underperformed its benchmark on a risk-adjusted basis.
Third, the Beta values are low (-0.1, 0.1, 0.1), which suggest RXRX's price is not very sensitive to market movements.
Finally, the company's market capitalization has decreased from 4.0B to 2.2B over the periods, which might indicate investor concerns or market reevaluation of the company.

### 2. Recent Price Action

*   **Current Price:** $5.52
*   **Last Market Price:** $5.09
*   **Previous Close:** $5.52
*   **Change:** -7.79% (Significant decrease)
*   **5-Day Moving Average:** 5.61
*   **20-Day Moving Average:** 5.82
*   **60-Day Moving Average:** 5.31

**Analysis:** RXRX experienced a notable price drop recently. The current price ($5.09) is below all moving averages, suggesting a short-term downtrend. The significant negative change (-7.79%) indicates potential negative sentiment or news affecting the stock.

### 3. Technical Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.329 (Low Risk)
*   **RSI:** 39.41 (Approaching oversold territory)
*   **PPO:** -0.67
*   **Hybrid Signal:** Cash_70%_Sell (70% of holdings - Caution - MRI:0.34)
*   **Delta Previous Relative Divergence (20-day):** -2.4 (Short-term downward trend)
*   **Expected Return:** -1024.9% (Very negative, indicating substantial potential underperformance vs. S&P 500 over a long-term investment horizon)

**Analysis:** The RSI suggests the stock might be approaching oversold territory, potentially indicating a possible short-term rebound. The PPO is negative, supporting the downtrend. The Hybrid Signal suggests caution, recommending a high cash position.  The negative expected return is a major red flag, signaling significant risks associated with long-term investment in RXRX based on current data. The sharp price drop reflected in the "change" figure likely contributed to the negative signals.

### 4. Recent News & Significant Events

*   **[2025-08-17]:** Major business developments, regulatory changes, or market events.
*   **[2025-08-16]:** Analyst discussions on recent performance and industry/economic context.
*   **[2025-08-19]:** Notable stock volatility due to recent news, earnings, or executive actions.
*   **[2025-08-18]:** Market experts highlight both risks and opportunities.

**Analysis:** The recent news suggests that RXRX is experiencing significant volatility and is subject to both positive and negative factors. Investors should closely monitor company announcements and news for further developments.

### 5. Recent Earnings Analysis

| Date       | EPS   | Revenue |
| :---------- | :----- | :------- |
| 2025-08-05 | -0.41 | 0.02 B$ |
| 2025-05-05 | -0.50 | 0.01 B$ |
| 2024-11-06 | -0.34 | 0.03 B$ |
| 2024-08-08 | -0.40 | 0.01 B$ |
| 2025-08-05 | -0.40 | 0.01 B$ |

**Analysis:** The company consistently reports negative EPS (Earnings Per Share), indicating unprofitability. Revenue fluctuates but remains relatively low. The consistent losses are a concern.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
| :------------- | :-------- | :--------------- |
| 2025-06-30   | $0.02B  | -5.54%         |
| 2025-03-31   | $0.01B  | -47.31%         |
| 2024-12-31   | $0.00B  | -183.62%        |
| 2024-09-30   | $0.03B  | 53.69%          |
| 2024-06-30   | $0.01B  | 36.14%          |

**Capital and Profitability:**

| Quarter      | Equity   | ROE      |
| :------------- | :--------- | :--------- |
| 2025-06-30   | $0.92B   | -18.70%  |
| 2025-03-31   | $0.93B   | -21.68%  |
| 2024-12-31   | $1.03B   | -17.29%  |
| 2024-09-30   | $0.52B   | -18.27%  |
| 2024-06-30   | $0.58B   | -16.69%  |

**Analysis:**
The profit margins are generally negative, with some quarters showing positive margins. However, the negative values are substantial and concerning.
The Return on Equity (ROE) is consistently negative, confirming the company's inability to generate profits from shareholder equity.
Despite the company maintaining a large equity, its low or negative ROE implies inefficiencies in its usage.

### 7. Overall Assessment

Based on the provided data, RXRX presents a **high-risk investment**.

*   **Underperformance:** Significant underperformance relative to the S&P 500.
*   **Volatility:** Recent news and price action indicate high volatility.
*   **Unprofitability:** Consistent negative EPS and ROE highlight the company's struggles with profitability.
*   **Deteriorating Financials:** Negative profit margins and decreasing ROE, although equity remains high.
*   **Technical Signals:** Technical indicators suggest a short-term downtrend with potential for a rebound, but the overall outlook is bearish.
*   **Market Risk:** The MRI is low.
*   **Hybrid Signal:** Hybrid Signal recommend Caution.

**Recommendation:** Given the significant risks, a cautious approach is warranted. Investors should closely monitor the company's upcoming announcements and financial results for any signs of improvement. The negative expected return suggests that, based on current data, a long-term investment may not be advisable.
